Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
Alpana Waghmare(University of Washington), Zainab Shahid(Quaid-i-Azam University), Michael Boeckh, Sanjeet Dadwal(City Of Hope National Medical Center), Steven A. Pergam(Seattle Cancer Care Alliance), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Genovefa A. Papanicolaou(Memorial Sloan Kettering Cancer Center), Maheen Z. Abidi(University of Colorado Denver), Mini Kamboj(Memorial Sloan Kettering Cancer Center), Zeinab El Boghdadly(The Ohio State University Wexner Medical Center)
Cited by 65
Related Papers
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
|Biology of Blood and Marrow Transplantation|2009|1.8k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
|Blood|2003|442
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
|Annals of Oncology|2021|326
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
|Clinical Infectious Diseases|2021|299